Evidence map›Paper›PMID 34696444›Full record

ArticleViruses2021

Evolution of SARS-CoV-2 Key Mutations in Vienna Detected by Large Scale Screening Program.

Jakob Thannesberger, Anna Edermayr, Alireza Karimi, Mathias Mueller, Ursula Karnthaler, Richard Gauss, Daniela Penz, Arnulf Ferlitsch, Christoph Steininger

Abstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jakob ThannesbergerDivision of Infectious Diseases, Department of Medicine 1, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-3738-0356
Anna EdermayrLifebrain Covid Laboratory GmbH, 1140 Vienna, Austria.
Alireza KarimiLifebrain Covid Laboratory GmbH, 1140 Vienna, Austria.
Mathias MuellerLifebrain Covid Laboratory GmbH, 1140 Vienna, Austria.
Ursula KarnthalerCity Government of Vienna, State Sanitary Directorate, 1200 Vienna, Austria.
Richard GaussCity Government of Vienna, Department for Strategic Health Care, 1200 Vienna, Austria.
Daniela PenzDivision of Gastroenterology and Nephrology, Department of Medicine 1, Hospital of St. John of God, 1020 Vienna, Austria.
Arnulf FerlitschDivision of Gastroenterology and Nephrology, Department of Medicine 1, Hospital of St. John of God, 1020 Vienna, Austria.
Christoph SteiningerDivision of Infectious Diseases, Department of Medicine 1, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-3500-7205

Funding

Austrian Science Fund FWF P 33546
6 · The paper itself

Abstract

Currently countries across the globe are preparing for the fourth wave of SARS-CoV-2 infections, which is mainly driven by the rapid spread of novel SARS-CoV-2 variants. Austria and, in particular, the capital city of Vienna, witnessed a disproportionally steep rise in SARS-CoV-2 infection rates during the last wave of infections. By the end of January 2021, the government of Vienna launched an innovative, state-wide SARS-CoV-2 screening program based on PCR analysis of self-collected mouthwash samples. More than 400,000 mouthwash samples were collected in Vienna during the third wave of infection from January to March 2021. All preanalytical and analytical steps were carried out in a highly standardized manner at a single certified testing center. SARS-CoV-2 specific PCR analysis revealed in these samples a positivity rate of 0.43%. The relative proportion of N501Y positive virus samples increased continually to 68% of weekly samples. Mutation K417N was detected only in three samples. With this study, we were able to map the temporal occurrence of SARS-CoV-2 variants in a highly unbiased manner. Positivity rates and variant prevalence rates in this study were lower than in other nationwide programs. The results presented in this study indicate that actual virus prevalence tends to be overestimated by surveillance programs such as results of cluster analysis or contact tracing programs.

Indexed as

AustriaCOVID-19COVID-19 TestingHumansMass ScreeningMutationPolymerase Chain ReactionPrevalenceSARS-CoV-2B.1.1.7B.1.351COVID-19K417NN501YSARS-CoV-2ViennaVOC

Identifiers

PMID34696444
PMCPMC8538562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.